Oral Microbiome Therapy Tied to Low Recurrence of C. Diff
A potential first-in-class investigational microbiome therapeutic, SER-109, was safe and observed to sustain low Clostridioides difficile (C. diff) recurrence rates for adults, according to the phase III, single-arm ECOSPOR IV study. Recurrence of C. diff infections occurred in 8.7% of patients at week 8 after receiving a short course of capsules containing purified Firmicutes bacteria […]